STAT+: Seattle scientists launch $95 million AI biology effort
Ultragenyx drug fails pivotal Phase 3, FDA's success at regulating unproven stem cells, and other biotech news
Ultragenyx drug fails pivotal Phase 3, FDA's success at regulating unproven stem cells, and other biotech news